

Global Cardiogenic Shock Market: Analysis By Treatment Type (Drugs, Mechanical Circulatory Support (MCS) Devices and Others), By End User (Hospitals & Clinics, Specialty Cardiac Centers, Ambulatory Surgical Centers and Others), By Region Size and Trends with Impact of COVID-19 and Forecast up to 2030

March 2025



Global Cardiogenic Shock Market: Coverage

Executive Summary and Scope

Introduction/Market Overview

Global Market Analysis

Regional Market Analysis

Impact of COVID

Dynamics

Competitive Landscape

Company Profiling

Global Cardiogenic Shock Market: Coverage

Scope of the Report

Attributes	Details
Title	Global Cardiogenic Shock Market: Analysis By Treatment Type (Drugs, Mechanical Circulatory Support (MCS) Devices and Others), By End User (Hospitals & Clinics, Specialty Cardiac Centers, Ambulatory Surgical Centers and Others), By Region Size and Trends with Impact of COVID-19 and Forecast up to 2030
Coverage	Global and Regional
Regional Coverage	North America (The US, Canada and Mexico), Europe (Germany, UK, France, Italy, Spain and Rest of Europe), Asia Pacific (China, Japan, India, South Korea and Rest of Asia Pacific) and Rest of the World
Market Influencing Variables	Growth Drivers, Challenges, Market Trends
Forecast Period of Market	2025-2030
Competition in the Market	Fragmented
Key Players	Abbott, Medtronic plc, Boston Scientific Corporation, AstraZeneca Plc, Roche Holdings AG, Bayer AG, Getinge, Johnson & Johnson (Abiomed), Viatris, Inc., Terumo Corporation, Endo International plc (Par Pharmaceutical), Windtree Therapeutics, Inc., ZOLL Medical Corporation

Global Cardiogenic Shock Market: Coverage

Executive Summary

Cardiogenic shock is a life-threatening condition in which the heart suddenly fails to pump enough blood to meet the body's needs. It is most commonly caused by a severe heart attack (myocardial infarction) but can also result from other heart conditions such as heart failure, arrhythmias, myocarditis, or valve disorders. The global cardiogenic shock market value in 2024 stood at US\$3.57 billion, and is expected to grow at a CAGR of 6.36% over the projected period of 2025-2030.


The cardiogenic shock market can be segmented on the basis of treatment type (drugs, mechanical circulatory support (MCS) devices and others), and end user (hospitals & clinics, specialty cardiac centers, ambulatory surgical centers and others). On the basis of treatment type, drugs segment dominated the market in 2024 due to their rapid availability, cost-effectiveness, and widespread use as the first-line treatment for stabilizing patients before considering mechanical circulatory support interventions. Based on end-user, hospitals segment dominated the market in 2024 due to the availability of advanced life-saving treatments, specialized cardiac care units, and the high patient influx requiring immediate critical care. On the basis of region, North America dominated the global cardiogenic shock market in 2024 due to the high prevalence of cardiovascular diseases, advanced healthcare infrastructure, strong presence of key market players, and increased adoption of innovative treatment technologies.

The COVID-19 pandemic initially disrupted the global cardiogenic shock market due to delays in non-emergency cardiac procedures, strained healthcare resources, and supply chain challenges. However, post-COVID-19, the market rebounded with increased investments in critical care infrastructure, growing awareness of cardiovascular complications linked to COVID-19, and accelerated adoption of advanced treatment modalities.

The global cardiogenic shock market has increased in 2024 and projections are made that the market would rise in the next five years i.e. 2025-2030 tremendously. The growth is driven by increase in the global geriatric population, increasing incidence of heart disease, growing healthcare expenditure, growing prevalence of sedentary lifestyle, rising awareness and early diagnosis etc. Further, the market is expected to grow, owing to rise in adoption of artificial intelligence, technological advancements, development of novel pharmacological therapies, rise in research and development activities, adoption of minimally invasive techniques, rising demand for point-of-care testing etc., yet the market faces some challenges, such as high cost of advanced therapies and devices, shortage of skilled healthcare professionals etc.

Cardiogenic Shock Market: Global Analysis


Global Cardiogenic Shock Market by Value



Global cardiogenic shock market valued at US\$... billion in 2024, increased as compared to US\$... billion in 2023. Global cardiogenic shock market is anticipated to reach up to US\$... billion by 2030, at a CAGR of%, from US\$... billion in 2025.


Cardiogenic Shock Market: Global Analysis

Global Cardiogenic Shock Market by Treatment Type; 2024



Treatment Type	Share
	(2024)
Drugs	xx%
Mechanical Circulatory Support Devices	xx%
Others	xx%


Global Cardiogenic Shock Market by End-user; 2024



End-user	Share
	(2024)
Hospitals & Clinics	xx%
Specialty Cardiac Centers	xx%
Ambulatory Surgical Centers	xx%
Others	xx%

Cardiogenic Shock Market: Global Analysis


Global Cardiogenic Shock Market by Region; 2024




Region	Share
Asia Pacific	xx%
Europe	xx%
North America	xx%
Latin America	xx%
Middle East and Africa	xx%

Global Cardiogenic Shock Market: Treatment Type Analysis

Global Drugs Cardiogenic Shock Market by Value




Global Mechanical Circulatory Support (MCS) Devices Cardiogenic Shock Market by Value




Treatment Type	CAGR (2025-30)
Drugs	xx%
Mechanical Circulatory Support Devices	xx%
Others	xx%

Global Cardiogenic Shock Market: End-user Analysis

Global Hospitals & Clinics Cardiogenic Shock Market by Value




Global Ambulatory Surgical Centers Cardiogenic Shock Market by Value




End-user	CAGR
	(2025-30)
Hospitals & Clinics	xx%
Specialty Cardiac Centers	xx%
Ambulatory Surgical Centers	xx%
Others	xx%

Global Cardiogenic Shock Market: Regional Analysis

North America Cardiogenic Shock Market by Value




Asia Pacific Cardiogenic Shock Market by Value




Region	CAGR
	(2025-30)
North America	xx%
Europe	xx%
Asia Pacific	xx%
Latin America	xx%
Middle East and Africa	xx%

North America Cardiogenic Shock Market: Analysis

North America Cardiogenic Shock Market by Region; 2024



The US Cardiogenic Shock Market by Value




Region	Share	CAGR (2025-30)
The US	xx%	xx%
Canada	xx%	xx%
Mexico	xx%	xx%

Europe Cardiogenic Shock Market: Analysis

Europe Cardiogenic Shock Market by Region; 2024




Germany Cardiogenic Shock Market by Value




Region	Share	CAGR (2025-30)
Germany	xx%	xx%
UK	xx%	xx%
France	xx%	xx%
Italy	xx%	xx%
Spain	xx%	xx%
Rest of Europe	xx%	xx%

Asia Pacific Cardiogenic Shock Market: Analysis

Asia Pacific Cardiogenic Shock Market by Region; 2024



China Cardiogenic Shock Market by Value



Region	Share	CAGR (2025-30)
China	xx%	xx%
India	xx%	xx%
Japan	xx%	xx%
South Korea	xx%	xx%
Rest of Asia Pacific	xx%	xx%

Global Cardiogenic Shock Market: Dynamics



Global Cardiogenic Shock Market: Competitive Landscape

Players Profiled

- Abbott, Medtronic plc
- Boston Scientific Corporation
- AstraZeneca Plc
- Roche Holdings AG
- Bayer AG
- Getinge,
- Johnson & Johnson (Abiomed)
- Viatris, Inc.
- Terumo Corporation
- Endo International plc (Par Pharmaceutical)
- Windtree Therapeutics, Inc.
- ZOLL Medical Corporation